Histone Demethylase

There are two classes of enzymes involved in histone methylation: methyltransferases and demethylases. While methyltransferases are responsible for establishing methylation patterns, demethylases are capable of removing methyl groups not only from histones but other proteins as well. Histone demethylases not only target methylated sites on histone tails but also interact with methylated sites on non-histone proteins, such as p53.

Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders.

JMJD1A (also named KDM3A) is a demethylasethat removes methyl from histone lysine H3K9. It plays important roles in various cellular processes, including spermatogenesis, energy metabolism, regulation of stem cell and gender display.

Jumonji domain-containing 3 (Jmjd3) has been identified as a histone demethylase, which specifically catalyzes the removal of methylation from H3K27me3.

Histone Demethylase Inhibitors & Antagonists

(rel)-Tranylcypromine D5 hydrochloride

(2-Phenylcyclopropylamine D5 hydrochloride) Cat. No.: HY-17447SA

(rel)-Tranylcypromine D5 hydrochloride (2-Phenylcyclopropylamine D5 hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS8351

(NSC51355) Cat. No.: HY-100744

AS8351 is a **KDM5B** inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CBB1003

Cat. No.: HY-15774

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1003 hydrochloride

Cat. No.: HY-15774A

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1007

Cat. No.: HY-15313

CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1007 hydrochloride

Cat. No.: HY-15313B

CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBB1007 trihydrochloride

Cat. No.: HY-15313C

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: 96.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Corin

Cat. No.: HY-111048

Corin is a dual inhibitor of histone lysine specific demethylase **(LSD1)** and histone deacetylase **(HDAC)**, with a K_i**(inact)** of 110 nM for LSD1 and an IC_{50} of 147 nM for HDAC1.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-455

Cat. No.: HY-100421

CPI-455 is a specific, pan-**KDM5** inhibitor with an **IC_{50}** of 10 nM for KDM5A.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Daminozide

Cat. No.: HY-13643

Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

DDP-38003 dihydrochloride

Cat. No.: HY-19612A

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an IC_{50} of 84 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDP-38003 trihydrochloride

Cat. No.: HY-19612B

DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an IC_{50} of 84 nM.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK 690 Hydrochloride

Cat. No.: HY-117226A

GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 **(LSD1)**, with a K_d value of 9 nM and a biochemical IC_{50} of 37 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-J1

Cat. No.: HY-15648

GSK-J1 is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with IC_{50} of 60 nM towards KDM6B. .



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

GSK-J1 lithium salt

Cat. No.: HY-15648D

GSK-J1 lithium salt is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with IC_{50} of 60 nM towards KDM6B.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

GSK-J2

Cat. No.: HY-15648A

GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK-J4

Cat. No.: HY-15648B

GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases **JMJD3/KDM6B** and **UTX/KDM6A** with IC_{50}s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC_{50} of 9 μM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-J4 hydrochloride

Cat. No.: HY-15648F

GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases **JMJD3/KDM6B** and **UTX/KDM6A** with IC_{50}s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC_{50} of 9 μM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-LSD1 dihydrochloride

Cat. No.: HY-100546A

GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (**LSD1**) inhibitor with an IC_{50} of 16 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK2879552

Cat. No.: HY-18632

GSK2879552 an orally active, selective and irreversible inhibitor of **lysine specific demethylase 1 (LSD1/ KDM1A)**, with potential antineoplastic activity.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2879552 dihydrochloride

Cat. No.: HY-18632A

GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of **lysine specific demethylase 1 (LSD1/KDM1A)**, with potential antineoplastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK467

Cat. No.: HY-116761

GSK467 is a cell penetrant and selective **KDM5B (JARID1B or PLU1)** inhibitor with a K_i of 10 nM, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IOX1

Cat. No.: HY-12304

IOX1, 5-Carboxy-8-hydroxyquinoline, is a potent broadspectrum inhibitor of **2OG** oxygenases, including the **JmjC** demethylases. IOX1 inhibits KDM4C, KDM4E, KDM2A, KDM3A and KDM6B with IC_{50} values of 0.6 μM, 2.3 μM, 1.8 μM, 0.1 μM and 1.4 μM, respectively. IOX1 also inhibits ALKBH5.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JIB-04

Cat. No.: HY-13953

JIB-04 is a pan-selective **Jumonji histone demethylase** inihibitor with IC_{50}s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

KDM2A/7A-IN-1

Cat. No.: HY-108706

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of **histone lysine demethylases KDM2A/7A**, with an IC_{50} of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4-IN-2

Cat. No.: HY-128343

KDM4-IN-2 (Compound 19a) is a potent and selective **KDM4/KDM5** dual inhibitor with K_is of 4 and 7 nM for KDM4A and KDM5B, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4D-IN-1

Cat. No.: HY-101928

KDM4D-IN-1 is a new **histone lysine demethylase 4D** (**KDM4D**) inhibitor with an IC_{50} value of 0.41±0.03 μM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5-C70

Cat. No.: HY-120400

KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-**KDM5 histone demethylase** inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg, 250 mg

KDM5-IN-1

Cat. No.: HY-100422

KDM5-IN-1 is a potent, selective and orally bioavailable **KDM5** inhibitor with an IC_{50} of 15.1 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5A-IN-1

Cat. No.: HY-100014

KDM5A-IN-1 is a potent, orally bioavailable pan-**histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 45 nM, 56 nM and 55 nM for **KDM5A**, **KDM5B** and **KDM5C**, respectively, and with an EC_{50} value of 960 nM for PC9 H3K4Me3.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDOAM-25

Cat. No.: HY-102047

KDOAM-25 is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KDOAM-25 citrate

Cat. No.: HY-102047B

KDOAM-25 citrate is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

KDOAM-25 trihydrochloride

Cat. No.: HY-102047A

KDOAM-25 trihydrochloride is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-2-Hydroxyglutaric acid

((S)-2-Hydroxyglutaric acid)

Cat. No.: HY-113039

L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit **histone demethylases** and hence promote histone methylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-2-Hydroxyglutaric acid disodium

((S)-2-Hydroxyglutaric acid disodium)

Cat. No.: HY-W015114

L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit **histone demethylases** and hence promote histone methylation.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

LSD1-IN-5

Cat. No.: HY-100859

LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LSD1-IN-6

Cat. No.: HY-100860

LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LSD1-IN-7 benzenesulfonate

Cat. No.: HY-129388B

LSD1-IN-7 benzenesulfonate is a potent and orally active inhibitor of **lysine specific demethylase-1 (LSD1)** with anticancer activity extracted from patent WO2017079670A1, compound 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LSD1-IN-7 Methylbenzenesulfonate

Cat. No.: HY-129388

LSD1-IN-7 Methylbenzenesulfonate is a potent and orally active inhibitor of **lysine specific demethylase-1 (LSD1)** with anticancer activity extracted from patent WO2017079670A1, compound 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-p.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML324

Cat. No.: HY-12725

ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

NCGC00244536

(KDM4B Inhibitor B3) Cat. No.: HY-101799

NCGC00244536 is a potent **KDM4B** inhibitor with an IC_{50} of 10 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NCGC00247743

Cat. No.: HY-112308

NCGC00247743 is a histone lysine demethylase **KDM4** inhibitor.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

OG-L002

Cat. No.: HY-19333

OG-L002 is a potent and highly selective **LSD1** inhibitor with an IC_{50} of 0.02 μM. OG-L002 is a potent **monoamine oxidases (MAO)** inhibitor with IC_{50}s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of **HSV IE** genes.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ORY-1001(trans)

Cat. No.: HY-12782T

ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (**KDM1A/LSD1**) inhibitor.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PBIT

Cat. No.: HY-101451

PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (**JARID1**) enzymes. PBIT inhibits **JARID1B** (**KDM5B** or **PLU1**) histone demethylase with an IC_{50} of about 3 μM . PBIT also inhibits **JARID1A** and **JARID1C** with IC_{50}s of 6 μM and 4.9 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Procaine

Cat. No.: HY-B0546

Procaine is a **DNA-demethylating** agent. Procaine acts through multiple targets and has a slow onset and a short duration of action.



Purity: 99.07%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Procaine hydrochloride

Cat. No.: HY-B0546A

Procaine hydrochloride is a **DNA-demethylating** agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.



Purity: 99.95%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

QC6352

Cat. No.: HY-104048

QC6352 is an orally available, selective and potent **KDM4C** inhibitor with an IC_{50} of 35 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S2101

Cat. No.: HY-110277

S2101 is a **lysine-specific demethylase 1** (**LSD1**) inhibitor with an IC_{50} of 0.99 μM, K_i of 0.61 μM and K_{inact}/K_i of 4560 M/s.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S2116

Cat. No.: HY-136522

S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1)** inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S2157

Cat. No.: HY-136523

S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1)** inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seclidemstat

(SP-2577)

Cat. No.: HY-103713

Seclidemstat (SP-2577) is a potent and orally bioavailable **LSD1** inhibitor, with a mean IC_{50} of 127 nM.



Purity: 98.78%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SP2509

Cat. No.: HY-12635

SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1)** with IC_{50} of 13 nM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

T-3775440 hydrochloride

Cat. No.: HY-103085

T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase **(LSD1)** inhibitor with an IC_{50} value of 2.1 nM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T-448

Cat. No.: HY-122635A

T-448 is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase)**, with an IC_{50} of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

T-448 free base

Cat. No.: HY-122635

T-448 free base is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase)**, with an IC_{50} of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tranylcypromine hemisulfate (dl-Tranylcypromine hemisulfate; trans-2-Phenylcyclopropylamine hemisulfate salt)

Cat. No.: HY-B1496

Tranylcypromine hemisulfate (dl-Tranylcypromine hemisulfate) is an irreversible, nonselective **monoamine oxidase (MAO)** inhibitor used in the treatment of depression.



Purity: 99.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Vafidemstat

(ORY-2001)

Cat. No.: HY-112623

Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (**LSD1**)/**MAO-B** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

YUKA1

Cat. No.: HY-100764

YUKA1 is a potent and cell permeable Lysine demethylase 5A (**KDM5A**) inhibitor, with an IC_{50} of 2.66 μM, less active on KDM5C (IC_{50}, 7.12 μM), and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 increases H3K4me3 levels in human cells with anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg